Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD3/MUC1 antibody-armed PD-1 inhibitor-induced cytokine-induced killer cells

A preparation of cytokine-induced killer cells (CIKs), which have been exposed, ex vivo, to a specific set of cytokines and a programmed cell death protein 1 (PD-1) inhibitor, mixed with a bispecific anti-cluster of differentiation 3 (CD3)/anti-mucin-1 (MUC1) antibody, with potential anti-tumor cytotoxic activity. Upon administration of the anti-CD3/MUC1 antibody-armed PD-1 inhibitor-induced CIKs, the antibody moiety binds to both CD3 on the CIKs and MUC1 on cancer cells. This crosslinks the CIKs and tumor cells, which allows the CIKs to target and lyse MUC1-expressing cancer cells. PD-1 blockade activates the CIKs. The cytokines used, usually interferon-gamma (IFNg), interleukin 1 (IL-1), and IL-2, stimulate the proliferation and maturation of peripheral blood mononuclear cells (PBMCs) into CIK cells. Anti-CD3 stimulation allows for the CIKs' improved lytic activity.
Synonym:anti-CD3/MUC1-armed PD-1 inhibitor-induced CIK cells
PD-1 activated CIK armed with anti-CD3/Anti-MUC1 bispecific antibody
Search NCI's Drug Dictionary